Anticytokine therapy in autoimmune diseases.

Autoimmune reaction and inflammation observed in autoimmune diseases may be caused by the deregulated production of cytokines. Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities such as support of hematopoiesis, regulation of acute phase reactions, and generation of immune responses. Uncontrolled hyperproduction of IL-6 causes plasmacytosis, hyper-gamma-globulinemia, thrombocytosis, mesangial cell proliferation of the kidney as well as inflammatory symptoms which are frequently observed in autoimmune diseases. Thus, interference with IL-6 signal transduction may be useful for autoimmune disease therapy. The pathogenic significance of IL-6 in autoimmune disorders and new therapeutic approaches involving blocking of IL-6 signal transduction are discussed.

[1]  G. Firestein,et al.  Anticytokine therapy in rheumatoid arthritis. , 1997, The New England journal of medicine.

[2]  T. Kishimoto,et al.  Plasma cell dyscrasias. , 1997, Advances in immunology.

[3]  R. Zinkernagel,et al.  Immunopathology or Organ‐Specific Autoimmunity as a Consequence of Virus Infection , 1996, Immunological reviews.

[4]  Y. Shima,et al.  Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.

[5]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[6]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Saldanha,et al.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer research.

[8]  D. Wendling,et al.  Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. , 1993, The Journal of rheumatology.

[9]  T. Kishimoto,et al.  Interleukin-6 in autoimmune disorders. , 1992, Seminars in immunology.

[10]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[11]  H. Mcdevitt,et al.  Antigen Recognition and Peptide‐Mediated Immunotherapy in Autoimmune Disease , 1990, Immunological reviews.

[12]  K. Matsumoto,et al.  Interleukin 6 and expression of its receptor on epidermal keratinocytes. , 1990, Cytokine.

[13]  A. Muraguchi,et al.  Involvement of IL-6 in mesangial proliferative glomerulonephritis. , 1989, Journal of immunology.

[14]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[15]  T. Hirano,et al.  Interleukin-6 is a potent thrombopoietic factor in vivo in mice. , 1989, Blood.

[16]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[17]  T. Ulich,et al.  In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. , 1989, Blood.

[18]  T. Hirano,et al.  IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. , 1988, Journal of immunology.

[19]  A. Okano,et al.  Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture , 1988, The Journal of experimental medicine.

[20]  Toshio Hirano,et al.  Recombinant human interleukin‐6 (IL‐6/BSF‐2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes , 1988, FEBS letters.

[21]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Hirano,et al.  Recombinant human B cell stimulatory factor 2 (BSF‐2/IFN‐β2) regulates β‐fibrinogen and albumin mRNA levels in Fao‐9 cells , 1987 .

[23]  T. Hirano,et al.  Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines. , 1987, Immunology letters.

[24]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[25]  N. Nicola,et al.  Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. , 1983, The Journal of biological chemistry.

[26]  T. Kishimoto,et al.  Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. , 1982, Journal of immunology.

[27]  T. Kishimoto,et al.  T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. , 1981, Journal of immunology.

[28]  B. Castleman,et al.  Hyaline‐vascular and plasma‐cell types of giant lymph node hyperplasia of the mediastinum and other locations , 1972 .

[29]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.